- Home
- VIVO vs EQ Comparison
VIVO vs EQ Comparison
Compare VIVO & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VIVO | EQ |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.2M | 89.4M |
| IPO Year | 2016 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VIVO | EQ |
|---|---|---|
| Price | $2.28 | $1.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.56 |
| AVG Volume (30 Days) | ★ 1.1M | 312.5K |
| Earning Date | 11-02-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | $1,116.11 | N/A |
| Revenue Next Year | $186.67 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.43 | $1.16 |
| 52 Week High | $6.86 | $6.20 |
Technical Indicators
Market Signals| Indicator | VIVO | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 47.48 | 40.62 |
| Support Level | $1.97 | $1.24 |
| Resistance Level | $4.29 | $1.51 |
| Average True Range (ATR) | 0.31 | 0.12 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 61.57 | 15.79 |
Price Performance
Historical ComparisonAbout VIVO VivoPower PLC Ordinary Shares
VivoPower PLC is engaged in building, owning, and leasing powered land and data center infrastructure for AI compute applications. The group delivers specialized infrastructure solutions across the AI Data Centers, Power-to-X, and Electric Mobility. It is develop and operated infrastructure that enables sovereign nations and institutional partners to secure control over power, data, and national intelligence, supporting AI, compute-intensive workloads, and energy transition use cases.
About EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.